Bobin, A., Zhang, R., Morisse, M., Schavgoulidze, A., Ragot, S., Roul, C., Chalopin, T., Montes, L., Dib, M., Tiab, M., Piocelle, F. O., Braun, T., Gay, J., Araujo, C., Tabrizi, R., Vincent, L., Santagostino, A., Garnier, K., Dhahri, D., Mohty, M., Macro, M., Roussel, M., Karlin, L., Moreau, P., Touzeau, C., Perrot, A., Facon, T., Hulin, C., Corre, J., Manier, S., Leleu, X. (2025). Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05). Blood. https://doi.org/10.1182/blood-2025-2275